Kolexia
Garnier-Tixidre Claire Oncologie médicale
Garnier-Tixidre Claire
Oncologie médicale
Selarl Institut De Cancerologie De Provence
Aix-en-Provence, France
53 Activités
185 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs du sein Carcinome épithélial de l'ovaire Fatigue Neutropénie Lymphopénie Métastase tumorale Tumeurs gastro-intestinales Tumeurs du cerveau

Collaborateurs

Voir plus
Leyronnas Cecile
Leyronnas Cecile
Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Stefani Laetitia
Stefani Laetitia
Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France

Industries

Voir plus
Lilly
8 collaboration(s)
Dernière en 2023
Daiichi Sankyo
5 collaboration(s)
Dernière en 2023
Novartis
3 collaboration(s)
Dernière en 2022
Pfizer
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
QUALIOR: Study Evaluating the Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program, for Metastatic Cancer Patients Receiving Oral Targeted Therapy: The UNICANCER SdS 01 QUALIOR Study
Essai Clinique (Unicancer)   07 novembre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023
ABLE02: A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
Essai Clinique (Centre Léon-Bérard)   29 août 2023
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
The Lancet. Oncology   29 septembre 2022
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
European journal of cancer (Oxford, England : 1990)   28 septembre 2021
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients.
Frontiers in pharmacology   20 septembre 2021
1680P Feasibility of home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase II study
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.
2021 ASCO Annual Meeting I   28 mai 2021
Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial.
BMC cancer   09 octobre 2020
823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020